

# Overview of the Office of Blood Research and Review Device Regulation

**Anne Eder, M.D., Ph.D.**

Office of Blood Research and Review  
CBER


## Overview:

- Office of Blood Research and Review (OBRR)
- Regulation of devices in OBRR
- Guidance, Advisory Committees, Standards
- What's new? Resources for developers
- Today's meeting – Outline


## Overview:

- **Office of Blood Research and Review (OBRR)**
- Regulation of devices in OBRR
- Guidance, Advisory Committees, Standards
- What's new? Resources for developers
- Today's meeting – Outline

# CBER Organizational Chart



# OBRR Organizational Chart



# Devices Reviewed by OBRR

## DETTD

- Blood donor screening and supplemental tests
  - Babesia, Chagas, CMV, HBsAg, HBc, anti-HBV, HCV, HIV, Syphilis, WNV, Zika
- Source Plasma donor screening tests
- Retroviral diagnostic tests (HIV/HTLV)
  - Diagnosis
  - Monitoring
  - Supplemental

## DBCD

- Blood grouping reagents
- Reagent Red Blood Cells
- Anti-Human Globulin
- Automated immunochemistry analyzers
- Molecular erythrocyte typing tests
- HLA, HNA, HPA - antigen and antibody test kits
- Bacterial detection tests

# Offices that Review or Contribute to OBRR Submissions

- Office of Biostatistics and Epidemiology (OBE)
- Office of Compliance and Biologics Quality (OCBQ)
  - Manufacturing, CMC, Quality Systems
  - Lot release
  - Compliance, adverse event reporting, labeling
  - Inspections
- Office of Tissues and Advanced Therapy (OTAT)
  - Cadaveric claims (heart beating or non-heart beating)
- Office of Product Evaluation and Quality (OPEQ), OHT7 (formerly OIR), Center for Devices and Radiological Health (CDRH): CLIA categorization

## Overview:

- Office of Blood Research and Review (OBRR)
- **Regulation of devices in OBRR**
- Guidance, Advisory Committees, Standards
- What's new? Resources for developers
- Today's meeting – Outline



## In Vitro Diagnostics (IVDs) are:

- Reagents, instruments, and systems used in diagnosis of disease or other conditions...in order to cure, mitigate, treat, or prevent disease.
- Intended for use in the collection, preparation, and examination of specimens taken from the human body.
- Medical devices per 201(h) of Food, Drug, & Cosmetic (FD&C) Act
- May also be biologic products subject to section 351 of Public Health Services Act

# Governing Acts and Regulations

Most OBRR devices are regulated under two acts and two sets of regulations

- Public Health Service Act (42 U.S.C. sec. 351):
  - Blood and blood products are therapeutic biological products
  - Tests used to ensure that blood is pure, potent, safe, effective
  - Regulated under 21 CFR 600s
- Food, Drug and Cosmetics Act (21 U.S.C. sec. 301):
  - In vitro diagnostic devices
  - Regulated under 21 CFR 800s

# Device Review is Based on the Intended Use

Intended Use (IU) includes:

- What indication?
- What population?
- What samples?
- What mode of operation?
- What other clinical information?

# Intended Use

ACME<sup>®</sup> WNV test for use on Acme<sup>®</sup> 103i Systems, is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.

This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors.

This test is not intended for use as an aid in diagnosis of WNV infection.

# Intended Use

ACME<sup>®</sup> WNV test for use on Acme<sup>®</sup> 103i Systems, is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.

Name/Instrument

Analyte

Sample

This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors.

This test is not intended for use as an aid in diagnosis of WNV infection.

# Intended Use

ACME<sup>®</sup> WNV test for use on Acme<sup>®</sup> 103i Systems, is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.

This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors.

This test is not intended for use as an aid in diagnosis of WNV infection.



Indication

# Intended Use

ACME<sup>®</sup> WNV test for use on Acme<sup>®</sup> 103i Systems, is a qualitative in vitro nucleic acid screening test for the direct detection of West Nile virus (WNV) RNA in human plasma.

This test is intended for use to screen donor samples for WNV RNA in plasma samples from individual human donors, including donors of whole blood and blood components, as well as other living donors.

This test is not intended for use as an aid in diagnosis of WNV infection.



Limitation



# Basis of Pre-market Device Review: Safety and Effectiveness

## Safety

...the **probable benefits to health** from use of the device for its **intended uses and conditions of use**, when accompanied by adequate directions and warnings against unsafe use, **outweigh any probable risks.** [21 CFR 860.7(d)(1)]

## Effectiveness

...the use of the device for **its intended uses and conditions of use**, when accompanied by adequate directions for use and warnings against unsafe use, **will provide clinically significant results.** [21 CFR 860.7(e)(1)]



# Safety/Risks to Health

- **A false negative test result:**
  - Wrong result in compatibility testing: Transfusion of incompatible blood to a patient causing hemolytic transfusion reaction
  - Negative result in infectious disease testing: Transfusion of blood from infected donor causing disease in recipient
- **A false positive result:**
  - RhD+ result in RhD-negative pregnant woman resulting in missing RhD immunoglobulin shot and possible hemolytic disease of fetus and newborn
  - Positive for infectious disease: unnecessary follow-up testing, additional diagnostic studies, and psychological stress to the donor

# IVD Submission Types

	Class I	Class II		Class III	BLA
Decision	Marketed	510(k) cleared (SE/NSE)	De Novo Granted	PMA approved	Licensed
Marketing Authorization Standard	Registered and listed, cGMP	Predicate Device Substantial equivalence	Safety and effectiveness	Safety and effectiveness	Safety and effectiveness
Risk-based Inspections	Risk-based	Post-market	Post-market (may be pre)	Pre-, post-market, BIMO	Pre-, post-market, BIMO
Interactions	NA	Interactive Review (IR), Additional information (AI) request	IR, AI	IR, Major Deficiency letter (MDL)	IR, Complete response (CR)
Time to decision (FDA days)	NA	90 days	150 days	180 days 320 for panel track	10 months 6 months (priority)

# IVD Submission Types

	Class I	Class II		Class III	BLA
Decision	Marketed	510(k) cleared (SE/NSE)	De Novo Granted	PMA approved	Licensed
Marketing Authorization Standard	Registered and listed, cGMP	Predicate Device Substantial equivalence	Safety and effectiveness	Safety and effectiveness	Safety and effectiveness
Risk-based Inspections	Risk-based	Post-market	Post-market (may be pre)	Pre-, post-market, BIMO	Pre-, post-market, BIMO
Interactions	NA	Interactive Review (IR), Additional information (AI) request	IR, AI	IR, Major Deficiency letter (MDL)	IR, Complete response (CR)
Time to decision (FDA days)	NA	90 days	150 days	180 days 320 for panel track	10 months 6 months (priority)

# IVD Submission Types

	Class I	Class II		Class III	BLA
Decision	Marketed	510(k) cleared (SE/NSE)	De Novo Granted	PMA approved	Licensed
Marketing Authorization Standard	Registered and listed, cGMP	Predicate Device Substantial equivalence	Safety and effectiveness	Safety and effectiveness	Safety and effectiveness
Risk-based Inspections	Risk-based	Post-market	Post-market (may be pre)	Pre-, post-market, BIMO	Pre-, post-market, BIMO
Interactions	NA	Interactive Review (IR), Additional information (AI) request	IR, AI	IR, Major Deficiency letter (MDL)	IR, Complete response (CR)
Time to decision (FDA days)	NA	90 days	150 days	180 days 320 for panel track	10 months 6 months (priority)

# IVD Submission Types

	Class I	Class II		Class III	BLA
Decision	Marketed	510(k) cleared (SE/NSE)	De Novo Granted	PMA approved	Licensed
Marketing Authorization Standard	Registered and listed, cGMP	Predicate Device Substantial equivalence	Safety and effectiveness	Safety and effectiveness	Safety and effectiveness
Risk-based Inspections	Risk-based	Post-market	Post-market (may be pre)	Pre-, post-market, BIMO	Pre-, post-market, BIMO
Interactions	NA	Interactive Review (IR), Additional information (AI) request	IR, AI	IR, Major Deficiency letter (MDL)	IR, Complete response (CR)
Time to decision (FDA days)	NA	90 days	150 days	180 days 320 for panel track	10 months 6 months (priority)

# IVD Submission Types

	Class I	Class II		Class III	BLA
Decision	Marketed	510(k) cleared (SE/NSE)	De Novo Granted	PMA approved	Licensed
Marketing Authorization Standard	Registered and listed, cGMP	Predicate Device Substantial equivalence	Safety and effectiveness	Safety and effectiveness	Safety and effectiveness
Risk-based Inspections	Risk-based	Post-market	Post-market (may be pre)	Pre-, post-market, BIMO	Pre-, post-market, BIMO
Interactions	NA	Interactive Review (IR), Additional information (AI) request	IR, AI	IR, Major Deficiency letter (MDL)	IR, Complete response (CR)
Time to decision (FDA days)	NA	90 days	150 days	180 days 320 for panel track	10 months 6 months (priority)

# Change Management for Marketed Devices

	510(k) <sup>a</sup>	PMA <sup>b</sup>	BLA <sup>c</sup>
<b>Major changes</b> May effect safety and effectiveness (S&E) Require pre-approval	New 510(k)	180-day, Panel track, Manufacturing site change	Comparability, efficacy, Labeling, Manufacturing (PAS)
<b>Moderate changes-</b> Little effect on S&E- Notification	Special 510(k), abbreviated 510(k)	30-day notice, Real time, Labeling, CBE	CBE, CBE-30
<b>Minor changes-</b> No effect on S&E	CLIA categorization (CR)	Annual report	Annual report

## References

<sup>a</sup><https://www.fda.gov/media/99812/download>

<sup>b</sup><https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process>

<sup>c</sup><https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-biological-products>

# Representative Changes

	510(k)	PMA	BLA
<b>Major</b> New 510(k), 180-day, panel track	<ul style="list-style-type: none"> <li>•New antibody</li> <li>•Remove limitation</li> </ul>	<ul style="list-style-type: none"> <li>•New antibody</li> <li>•Mfg site change</li> </ul>	<ul style="list-style-type: none"> <li>•New key reagents</li> <li>•Mfg site change</li> </ul>
<b>Moderate</b> 30DN, CBE, CBE-30, special 510(k)	<ul style="list-style-type: none"> <li>•Add clinical data</li> <li>•Update reference range</li> </ul>	<ul style="list-style-type: none"> <li>•Add QC step</li> <li>•New cleaning process</li> </ul>	<ul style="list-style-type: none"> <li>•Automate process</li> <li>•Labeling changes</li> </ul>
<b>Minor</b> CLIA categorization, Annual report	<ul style="list-style-type: none"> <li>•Add a limitation</li> <li>•Clarify instructions</li> </ul>	<ul style="list-style-type: none"> <li>•Extend stability per approved protocol</li> <li>•Tighten specifications</li> </ul>	<ul style="list-style-type: none"> <li>•Add timepoints to stability protocol</li> <li>•Labeling changes</li> </ul>

## References

<sup>a</sup><https://www.fda.gov/media/99812/download>

<sup>b</sup><https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process>

<sup>c</sup><https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-biological-products>



## Overview:

- Office of Blood Research and Review (OBRR)
- Regulation of devices in OBRR
- **Guidance, Advisory Committees, Standards**
- What's new? Resources for developers
- Today's meeting – Outline

# FDA Guidance Homepage

## Search for FDA Guidance Documents

Subscribe to Email Updates

[f Share](#)
[Tweet](#)
[in LinkedIn](#)
[Email](#)
[Print](#)

**Search for FDA Guidance Documents**

---

[Search General and Cross-Cutting Topics Guidance Documents](#)

---

[Advisory Committee Guidance Documents](#)

---

[Clinical Trials Guidance Documents](#)

---

[Combination Products Guidance Documents](#)

---

[Import and Export Guidance Documents](#)

---

[International Council for Harmonisation \(ICH\) Guidance Documents](#)

---

[Cross-cutting Guidance Documents](#)

The table below lists all official FDA Guidance Documents and other regulatory guidance. You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.

This feature is provided to give a convenient way to search for all FDA guidance documents from a single location.

If you cannot find the document you're looking for here, you can browse separate collections of guidance documents by topic.

Go to Guidance Document Search

**Browse Guidance Documents By Topic** ▲

- [General and Cross-Cutting Topics](#)
- [Advisory Committees](#)
- [Animal and Veterinary](#)
- [Biologics](#)
- [Clinical Trials](#)

# Least Burdensome Guidance

Finalized Feb. 2019

“Least burdensome”: the minimum amount of information necessary to adequately address a relevant regulatory question or issue through the most efficient manner at the right time.

*Contains Nonbinding Recommendations*

**The Least Burdensome Provisions:  
Concept and Principles**

---


**Guidance for Industry and  
Food and Drug Administration Staff**

Document issued on February 5, 2019.

The draft of this document was issued on December 15, 2017.

This document supersedes “The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles,” issued on October 4, 2002.

For questions about this document regarding CDRH-regulated devices, contact the Office of the Center Director at (301) 796-6900. For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach and Development in CBER at 1-800-835-4709 or 240-402-8010 or by email at [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov).

 **U.S. FOOD & DRUG  
ADMINISTRATION**

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health  
Center for Biologics Evaluation and Research

1

# The Q-submission Program

Finalized May 2019  
Changes to timelines

*Contains Nonbinding Recommendations*

**Requests for Feedback and Meetings  
for Medical Device Submissions:  
The Q-Submission Program**

---

**Guidance for Industry and  
Food and Drug Administration Staff**


Document issued on May 7, 2019.

**This guidance supersedes “Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff,” dated September 29, 2017.**

For questions about this document regarding CDRH-regulated devices, contact ORP: Office of Regulatory Programs/DRP1: Division of Submission Support at 301-796-5640. For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently OMB control number. The OMB control number for this collection is 0910-0756 (expires January 31, 2020).

See additional PRA statement in Section V of the guidance.



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health  
Center for Biologics Evaluation and Research

# Guidances Applicable to Devices

- Device guidances

<https://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/devices-guidances>

- Application submission guidances

<https://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/application-submissions-guidances>

- MDUFA IV performance goals

<https://www.fda.gov/media/102699/download>



# Blood Products Advisory Committee (BPAC)

- FDA's Advisory Committees provide independent advice from outside experts on relevant issues
- Composition
  - Voting: Authorities knowledgeable in blood banking, medicine, immunology, epidemiology other professionals
  - Non-voting: Industry representative, consumer rep (device panels)
- Meet regularly to provide advice on issues of importance to FDA/CBER/OBRR
  - Specific device approvals as needed
  - Classification, reclassification of devices
  - Pathogen reduction of blood components

# Recognized Consensus Standards

- Standards produced by experts to present best practices for specific aspects of validation
- FDA recognizes certain standards

FDA Standards Website:  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>

FDA



C56-A

Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline

July 2012

This document provides background information on the mechanisms of hemolysis, icterus, lipemia interference; intended usefulness of HLL of HLL alert indices; availability of automatic systems; and interpretation, strengths, limitations, and verification of HLL indices in the clinical laboratory.

A guideline for global application developed through the International Organization for Standardization (ISO) and the American National Standards Institute (ANSI).

American National Standard

ANSI/AAMI/ISO 14971:2007/(R)2016  
Medical devices—Application of risk management to medical devices

The screenshot shows the FDA Standards Website search interface. At the top, there is a navigation bar with the FDA logo and the text "U.S. FOOD & DRUG ADMINISTRATION". Below this is a search bar with a "SEARCH" button. The main content area is titled "Recognized Consensus Standards" and includes a "Search Database" section with various search criteria: Standards Organization (dropdown menu), Standard Designation Number (text input), Standards Title or Keywords (text input), Specialty Task Group Area (dropdown menu), Product Code (text input), and Date of Recognition (text input with "to" and "from" fields). There are also "Quick Search", "Clear Form", and "Search" buttons. On the right side, there is a "Other Databases" section with a list of links to various databases.

## Overview:

- Office of Blood Research and Review (OBRR)
- Regulation of devices in OBRR
- Guidance, Advisory Committees, Standards
- **What's new? Resources for developers**
- Today's meeting – Outline



# What's New? Product Codes for BLA Devices

A screenshot of a web-based search interface titled "Search Database". The form includes several input fields: "Product Problem", "Product Class", "Event Type", "Manufacturer", "Model Number", "Report Number", "Brand Name", and "Product Code". The "Product Code" field contains the text "MTF" and is highlighted with a yellow border. A yellow arrow points from the word "Procode" to this field. At the bottom of the form, there are date pickers for "Date Report Received by FDA (mm/dd/yyyy)" with values "04/01/2019" and "04/30/2019", a "Records per Report Page" dropdown set to "10", and buttons for "Go to Simple Search", "Clear Form", and "Search".

Procode

- Random three-letter codes used for
  - Adverse event reporting
  - Searching databases
- Manufacturers will receive letters with new product codes (procodes)

# Resources for Sponsors

- Reagents
  - Reference panels for development
  - Analyte reference standards for validation
  - DNA reference samples
- Workshops
  - Disease-specific: Babesia spp.
  - Technology-specific: Next-Gen Sequencing
  - Education and Outreach: IVD roundtable



# CBER Office of Communications, Outreach & Development

Manufacturer's Assistance and Technical Training Branch  
(MATTB)

- How to submit-eCopy, etc.
- Registration and listing
- Email
- User fees

Email: [Industry.biologics@fda.hhs.gov](mailto:Industry.biologics@fda.hhs.gov)

Phone: 240-402-8020 or 1800-835-4709

Website: <https://www.fda.gov/vaccines-blood-biologics/industry-biologics/manufacturers-assistance-and-technical-training-branch-mattb>

## Overview:

- Office of Blood Research and Review (OBRR)
- Regulation of devices in OBRR
- Guidance, Advisory Committees, Standards
- What's new? Resources for developers
- **Today's meeting – Outline**

# Elements Covered in the Workshop



## Pre-Market: Common Elements

**PreSubmission**  
**Iwona Fijalkowska**

**Lot Release**  
**Kori Francis**

**IND/IDE**  
**Caren Chancey**

**BIMO**  
**Bhanu Kannan**

**CMC**  
**Rana Nagarkatti**  
**Lori Peters**

**Pre-Licensure  
Inspection**  
**Nicole Li**

**Software**  
**Lisa Simone**

Not every element applies to every device

# Elements Covered in the Workshop

## Pre-Market: Indication-Specific Considerations

**Infectious Disease  
Screening**

**Donor-Recipient  
Compatibility**

**Analytical  
Krishna Ketha**

**Immunohematology  
Kimberly Bigler  
Annette Ragosta**

**Clinical  
Babita Mahajan**

**Molecular Tests  
Zhugong (Jason) Liu**

**Cadaveric Claims  
Brychan Clark**

Not every element applies to every device

# Elements Covered in the Workshop

**Post Market**

**CLIA Categorization**  
**Peter Tobin**

**Biological Product  
Deviation Reporting**  
**Sharon O'Callaghan**

**Medical Device  
Reporting**  
**Bima Patel**

Not every element applies to every device



Thank you!

Anne Eder

[Anne.Eder@fda.hhs.gov](mailto:Anne.Eder@fda.hhs.gov)